Anti-PD-L1 antibody, durvalumab, is notable for its entry into several HNSCC clinical trials together with tremelimumab, the anti-CTLA-4 mAb (see Figure 5). This evidence concerns the gene CTLA4 and head and neck squamous cell carcinoma.